<DOC>
	<DOCNO>NCT02798458</DOCNO>
	<brief_summary>Patients undergo SmartPill test gain additional understanding Fabry disease manifestation via motility abnormality order improve symptom target therapy . An additional Endoscopic mucosal resection may perform qualify patient . Tissue analysis biopsy include evaluation abnormality cellular structure morphology correlation gastrointestinal complaint patient comparison age match non-Fabry patient tissue . The hypothesis patient fabry disease abnormal motility correlate patient symptoms quality life note questionnaire .</brief_summary>
	<brief_title>Evaluation Gastrointestinal Manifestation Fabry 's Disease</brief_title>
	<detailed_description>Background : Gastrointestinal manifestation abdominal pain , diarrhea nausea prominent , although typically non life-threatening , frequently cause significant morbidity burden patient Fabry disease . Additional depth understand gastrointestinal symptom pathophysiology Fabry disease acutely need order develop specific evaluation symptom advance treatment patient . Hypothesis : Patients gastrointestinal ( GI ) symptom delay motility SmartPill study , abnormal histologic finding mucosal resection symptom correlate abnormal histologic SmartPill finding . By gain additional insight characterization symptom relationship dysmotility , anticipate improve focused adjunct therapy patient . Methods : This study consist screen visit , SmartPill test procedure visit , follow visit subject enrol study . Fifteen patient , clinically warrant sigmoidoscopy , ask also complete endoscopic mucosal resection ( EMR ) visit addition aspect study . Thus , subject report study site least 3 visit 4 visit .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Adults age 1865 year diagnose Fabry disease either enzyme testing male enzyme and/or genetically confirm mutation female . Adults Fabry disease gastrointestinal complaint within past year . Endoscopic Mucosal Resection ONLY Symptomatic subject necessitate sigmoidoscopy enzyme replacement therapy naive OR le 6 month treatment . 1 . Fabry disease concomitant gastrointestinal diagnosis ( Example : Inflammatory Bowel Disease , Celiac Disease ) 2 . Pregnancy 3 . Endoscopic mucosal resection exclusion : 1 . Any contraindication conscious sedation , 2 . Contraindication endoscopy , 3 . Untreated unmanageable coaguloapathy , 4 . Thrombocytopenia ( &lt; 50 ) . 5 . Patient ERT 6 month . 4 . Exclusions SmartPill : 1 . Previous history bezoars . 2 . Prior GI surgery except cholecystectomy , appendectomy , Nissen fundoplication . 3 . Any abdominal surgery within past 3 month 4 . History diverticulitis , diverticular stricture , intestinal stricture 5 . Tobacco use within eight hour prior capsule ingestion initial 8hour record Day 0 Ingestion visit . 6 . Alcohol use within eight hour prior capsule ingestion throughout entire monitoring period ( 5 day ) . 7 . BMI &gt; 38 8 . Allergies component SmartBar 9 . Use medical device pacemaker , infusion pump , insulin pump . 10 . Uncontrolled diabetes hemoglobin A1C great 10 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Fabry 's Disease</keyword>
	<keyword>Fabry</keyword>
</DOC>